Apellis Pharmaceuticals aims to change the way chronic inflammatory diseases are treated by modifying diseases rather than suppressing symptoms.
Apellis is an early stage biotechnology company focused on developing innovative therapeutics, primarily in the area of severe asthma and chronic obstructive pulmonary disease (COPD). It has a second program aimed at protecting red blood cells against immune destruction. Apellis assembled its pipeline of anti-inflammatory products through a combination of in-licensing of preclinical compounds and in-house research and development.
Product & Technology Spotlight
Apellis is a biotechnology company located in Louisville, KY that emerged from a successful transaction between Potentia Pharmaceuticals, Inc. and Alcon Research, Ltd in October 2009 in which Alcon licensed the ocular applications of Potentia’s family of complement inhibitors. Apellis holds the worldwide exclusive rights to the extra-ocular uses of these compounds (Apellis’ lead compound is APL-1). Apellis’ experienced management team came entirely from Potentia. APL-1, formerly called POT-4, is currently in Phase II clinical trials for age-related macular degeneration. In 2012 Apellis will launch two extra-ocular clinical programs for APL-1.
- October 2012 Apellis Pharmaceuticals Named 2012 Hot Dozen Company more »
- August 2011 Courier-Journal Article: How to Launch a Wonder Drug more »
- October 2009 Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon more »